Evidence map›Paper›PMID 34458833›Full record

ArticleRSC chemical biology2021

Leucine-rich alpha-2-glycoprotein 1 (LRG1) as a novel ADC target.

Faiza Javaid, Camilla Pilotti, Carlotta Camilli, David Kallenberg, Calise Bahou, Jack Blackburn, James R Baker, John Greenwood, Stephen E Moss, Vijay Chudasama

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC chemical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. The critical role of LRG1 in pathological fibrosis.Journal of molecular medicine (Berlin, Germany) · 2025
    Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 3 countries.

Faiza JavaidUCL Department of Chemistry 20 Gordon Street London WC1H 0AJ UK v.chudasama@ucl.ac.uk.
Camilla PilottiUCL Institute of Ophthalmology 11-43 Bath Street London EC1V 9EL UK j.greenwood@ucl.ac.uk s.moss@ucl.ac.uk.
Carlotta CamilliUCL Institute of Ophthalmology 11-43 Bath Street London EC1V 9EL UK j.greenwood@ucl.ac.uk s.moss@ucl.ac.uk.
David KallenbergUCL Institute of Ophthalmology 11-43 Bath Street London EC1V 9EL UK j.greenwood@ucl.ac.uk s.moss@ucl.ac.uk.
Calise BahouUCL Department of Chemistry 20 Gordon Street London WC1H 0AJ UK v.chudasama@ucl.ac.uk.
Jack BlackburnUCL Institute of Ophthalmology 11-43 Bath Street London EC1V 9EL UK j.greenwood@ucl.ac.uk s.moss@ucl.ac.uk.
James R BakerUCL Department of Chemistry 20 Gordon Street London WC1H 0AJ UK v.chudasama@ucl.ac.uk.ORCID https://orcid.org/0000-0002-7223-2279
John GreenwoodUCL Institute of Ophthalmology 11-43 Bath Street London EC1V 9EL UK j.greenwood@ucl.ac.uk s.moss@ucl.ac.uk.
Stephen E MossUCL Institute of Ophthalmology 11-43 Bath Street London EC1V 9EL UK j.greenwood@ucl.ac.uk s.moss@ucl.ac.uk.
Vijay ChudasamaUCL Department of Chemistry 20 Gordon Street London WC1H 0AJ UK v.chudasama@ucl.ac.uk.ORCID https://orcid.org/0000-0002-8876-3285
Institute of Ophthalmology · MXUniversity College Lahore · PK

Funding

Wellcome Trust
6 · The paper itself

Abstract

Leucine-rich alpha-2-glycoprotein 1 (LRG1) is present abundantly in the microenvironment of many tumours where it contributes to vascular dysfunction, which impedes the delivery of therapeutics. In this work we demonstrate that LRG1 is predominantly a non-internalising protein. We report the development of a novel antibody-drug conjugate (ADC) comprising the anti-LRG1 hinge-stabilised IgG4 monoclonal antibody Magacizumab coupled to the anti-mitotic payload monomethyl auristatin E (MMAE)

Identifiers

PMID34458833
PMCPMC8341842
OpenAlexW3167365283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.